Lee's Pharma unit gains exclusive rights to tecarfarin in Greater China and Thailand

22 September 2015

Privately-held US drug developer Armetheon has entered into an agreement with China Cardiovascular Focus, a subsidiary of Lee's Pharmaceutical (950: HK), to initiate advanced-stage clinical testing, manufacturing and commercialization of Armetheon's investigational oral anticoagulant, tecarfarin, in the greater China market including Mainland China, Hong Kong, Macau, and Taiwan as well as Thailand.

Under the terms of the deal, Lee's Pharma gains exclusive rights to develop and commercialize tecarfarin in the greater China market and Thailand. Tecarfarin is poised to enter into a final registration study (Tecarfarin for AntiCoagulation Trial, or TACT) in the USA under a Special Protocol Assessment (SPA) agreed with the Food and Drug Administration.

Terms of the collaboration

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK